Human tumor cells segregate into radiosensitivity groups that associate with ATM and TP53 status

Acta Oncologica

Volumn 46, Issue 5, 2007, Pages 628-638

  Williams, Jerry R ^a,b   Zhang, Yonggang ^a   Russell, James ^a,c   Koch, Cameron ^d   Little, John B ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA; K RAS PROTEIN; PROTEIN 14 3 3; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL SURVIVAL; CLONOGENESIS; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MISMATCH REPAIR; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RADIOSENSITIVITY; STATISTICAL SIGNIFICANCE; TUMOR CELL;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; EXONUCLEASES; GENE EXPRESSION; GENES, RAS; GLIOBLASTOMA; HUMANS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 34250314397     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860601080407     Document Type: Article

References (24)

1. Puck TT, Marcus PI. Action of X-rays on mammalian cells. J Exp Med 1956;103:653-66.
2. Thames HD Jr, Withers HR, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: Impliations for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982;8:219-26.
3. Fowler JF. The linear-quadratic model and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94.
4. Fowler JF. Dose-response curves for organ function in cell survival. Br J Radiol 1983;56:497-500.
5. Hall E. Radiobiology for the Radiologist. Chapter 3. Philadelphia: JB Lippincott; 1994.
6. Malaise EP, Fertil B, Chavaudra N, Guichard M. Distribution of radiation sensitivities for human tumor cells of specific histological types: Comparison of in vitro to in vivo data. Int J Radiat Oncol Biol Phys 1986;12:617-24.
7. West CM, Davidson SE, Roberts SA, Hunter RD. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 1997;76:1184-90.
8. Friedberg EC, Walker GC, Siede W. DNA Repair and Mutagenesis. Washington: ASM Press; 1995.
9. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in cellular response to DNA damage. Cancer Res 1991;51:6304-11.
10. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy. Radiother Oncol 1996;40:197-223.
11. Dahm-Daphi J. p53: Biology and role for cellular radiosensitivity. Strahlenther Onkol 2000;176:278-85.
12. Matsui Y, Tscuchida Y, Keng PC. Effects of p53 mutations on cellular sensitivity to ionizing radiation. Am J Clin Oncol 2001;24:486-90.
13. Weber KJ, Wenz F. p53, apoptosis and radiosensitivity - experimental and clinical data. Onkologie 2002;25:136-41.
14. Danielsen T, Smith-Sorensen B, Gronland HA, Hvidsten M, Barrensen-Dale AL, Rofstad EK. No association between radiosensitivyt and TP53 status, G1 arrest or in levels of p53, myc, ras or raf in human melanoma lines. Int J Radiat Biol 1999;75:1149-60.
15. Kandolier D, Zwrtk R, Ludwig C. TP53 genotype but not p53 immunohistochemistry results predicts response to preoperative short-term radiotherapy in operative rectal cancer. Ann Surg 2002;235:493-8.
16. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene 2002;21:6898-907.
17. Bunz F, Hwang PM, Torrance C, Waldmann T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Inv 1999;104:263-9.
18. Han TA, Hermeking H, Lengauer C, Janschek E, Ploner M, Hofbauer F, et al. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-20.
19. Waldman T, Zhang Y, Dillehay LE, Yu J, Kinzler K, Vogelstein B, et al. Cell cycle arrest vs. cell death in cancer therapy. Nat Med 1997;3:1034-6.
20. Sklar MD. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 1998;239:645-7.
21. Tribius S, Pidel A, Casper D. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys 2001;50:511-23.
22. Koi M, Umar A, Chauhan DP, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994;54:4308-12.
23. Chapman JD. Single hit mechanism of tumour cell killing by radiation. Int J Radiat Biol 2003;79:71-81.
24. Allison SG, Milner J. Remodelling chromatain on a global scale: A novel protective effect of p53. Carcinogenesis 2004;25:1551-7.